CRISPR/CAS9: A promising approach for the research and treatment of cardiovascular diseases


The development of gene-editing technology has been one of the biggest advances in biomedicine over the past two decades. Not only can it be used as a research tool to build a variety of disease models for the exploration of disease pathogenesis at the genetic level, it can also be used for prevention and treatment. This is done by intervening with the expression of target genes and carrying out precise molecular targeted therapy for diseases. The simple and flexible clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene-editing technology overcomes the limitations of zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). For this reason, it has rapidly become a preferred method for gene editing. As a new gene intervention method, CRISPR/Cas9 has been widely used in the clinical treatment of tumours and rare diseases; however, its application in the field of cardiovascular diseases is currently limited. This article reviews the application of the CRISPR/Cas9 editing technology in cardiovascular disease research and treatment, and discusses the limitations and prospects of this technology. Copyright © 2022 Elsevier Ltd. All rights reserved.

Authors Dong M, Liu J, Liu C, Wang H, Sun W, Liu B
Journal Pharmacological research
Publication Date 2022 Nov;185:106480
PubMed 36191879
DOI 10.1016/j.phrs.2022.106480

Research Projects

Cell Lines